New drug combo targets brain to soothe stubborn reflux
NCT ID NCT06945237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether adding a gut-brain neuromodulator (Flupentixol-Melitracen) to standard acid-reducing therapy (Lansoprazole) helps people with gastroesophageal reflux disease (GERD) who still have symptoms on acid suppressants alone. The trial enrolled 164 adults with GERD and measured symptom improvement using a standard questionnaire. The goal is to see if targeting brain-gut connections can provide better relief for this common condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flupentixol-Melitracen (a combination drug that affects brain chemicals) plus Lansoprazole (a standard acid-reducing drug)
What this could lead to
If successful, this could offer a new treatment option for GERD patients whose symptoms persist despite standard acid-reducing therapy, potentially improving quality of life.
What could go wrong
This is a small, completed trial with 164 participants, so results may not apply to everyone. The drug combination may cause side effects like drowsiness or allergic reactions, and the benefit over standard care may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiaotong university，renji hospital
Shanghai, Shanghai Municipality, China